Par Pharmaceutical Companies said John MacPhee had resigned as president of Strativa Pharmaceuticals and EVP Par Pharmaceutical “to pursue other interests” after six years with the company. Day-to-day oversight of Strativa, the company’s proprietary products division, will be assumed by Par chairman, president and CEO Patrick LePore on an interim basis. Woodcliff Lake, NJ-based Par’s focus is on marketing higher-barrier-to-entry generics and niche, innovative branded drugs.